Wistar Institute Appoints New CEO for November Start
The research organization selects a new leader to guide its 43 principal investigators beginning in late November.
Updated on Oct. 23, 2026 in People
Live Poll
Do you believe medical research institutions in your area are headed in the right direction?
The Wistar Institute has appointed Ronny Drapkin as its president and CEO, with his tenure set to begin on November 30, 2026. This leadership change comes as the Philadelphia-based research center continues to oversee 43 principal investigators.
Why it matters
The board selected Drapkin to sustain the scientific momentum established by his predecessor, aiming to leverage his background in interdisciplinary medicine to guide the institute's future research priorities.
The Wistar Institute currently supports 43 principal investigators, an organizational scale developed since its 1892 founding. It has operated as a National Cancer Institute-designated Basic Cancer Center since 1972.
The players
Ronny Drapkin
A professor in pathology at the Perelman School of Medicine who is transitioning to lead the Wistar Institute.
Wistar Institute
A long-standing Philadelphia-based biomedical research organization with 43 principal investigators.
National Cancer Institute
The federal agency that provides the Basic Cancer Center designation to qualifying research institutions.
Perelman School of Medicine
The medical school at the University of Pennsylvania where Drapkin holds a faculty position.
The details
The Wistar Board of Trustees selected Drapkin due to his dual focus on scientific credentials and experience managing complex, interdisciplinary environments. Drapkin currently holds a professorship in pathology in obstetrics and gynecology at the Perelman School of Medicine. He is tasked with overseeing the institute's ongoing research operations and maintaining its status as a foundational research hub.
Timeline
1892: Wistar Institute founded.
1972: Institute designated a Basic Cancer Center by National Cancer Institute.
October 2026: Ronny Drapkin appointed president and CEO.
November 30, 2026: Ronny Drapkin assumes the role.
Market Landscape
This leadership transition occurs within the framework of the institute’s status as a Basic Cancer Center, a designation held since 1972. The change in executive management follows a long-standing operational model rooted in its 1892 founding.
Operators in the biomedical and research sectors should monitor how Drapkin’s interdisciplinary approach impacts collaborative opportunities and local partnership criteria. Maintaining awareness of leadership shifts in major research hubs is essential for assessing regional innovation pipelines.
The takeaway
Drapkin's arrival signals a potential shift in how the institute manages its 43 principal investigators. Operators should track the institute’s upcoming public research announcements after November 30, 2026, to identify new opportunities for institutional collaboration.
What happens next
Ronny Drapkin will assume the role of president and CEO of the Wistar Institute on November 30, 2026.
Further reading
For more on local leadership changes, visit People.
Source note: This article includes information reported by Former Penn President Liz Magill earned $4.46 million the year following her resignation - The Daily Pennsylvanian.
Live Poll
Do you believe medical research institutions in your area are headed in the right direction?
